Rankings
▼
Calendar
COLL Q2 2018 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q2 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$73M
+1952.3% YoY
Gross Profit
$26M
35.9% margin
Operating Income
-$7M
-10.0% margin
Net Income
-$13M
-17.9% margin
EPS (Diluted)
$-0.40
QoQ Revenue Growth
+14.6%
Cash Flow
Operating Cash Flow
$56M
Free Cash Flow
$55M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$673M
Total Liabilities
$591M
Stockholders' Equity
$83M
Cash & Equivalents
$134M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$73M
$4M
+1952.3%
Gross Profit
$26M
$3M
+779.1%
Operating Income
-$7M
-$21M
+65.7%
Net Income
-$13M
-$21M
+38.2%
Revenue Segments
Nucynta
$55M
75%
Xtampza
$18M
25%
← FY 2018
All Quarters
Q3 2018 →